Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06853145 · ClinicalTrials.gov registry record · Early Phase 1

Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis

A Early Phase 1 study of Idiopathic Pulmonary Fibrosis, sponsored by University of Virginia.

Recruiting
Registry status
Early Phase 1
Development phase
6
Enrollment target
1
Study location

NCT06853145: Recruiting Early Phase 1 study of Idiopathic Pulmonary Fibrosis, sponsored by University of Virginia.

NCT06853145 is a Early Phase 1 study of Idiopathic Pulmonary Fibrosis that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 6 participants, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06853145, a Early Phase 1 study of Idiopathic Pulmonary Fibrosis, is actively recruiting participants, sponsored by University of Virginia.

RECRUITING
Registry status
Early Phase 1
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

Idiopathic pulmonary fibrosis has a poor prognosis with limited treatment options. The Investigator hypothesize hyperpolarized Xe129-MRI can be performed in patients with IPF and repeated over time which will detect deficiencies related to perfusion in the lung.

Primary Outcome

We will initially use descriptive statistics to describe the hyperpolarized Xe129 MRI indices and visualize their distribution using histograms. Paired t-test will be used to examine differences between baseline and follow-up hyperpolarized Xe129 MRI indices. Given that SA2 is to prove feasibility of accomplishing the MRI procedure, we have purposely opted to not adjust for the multiple MRI measurements that will be obtained.

Conditions Studied

Idiopathic Pulmonary Fibrosis

Interventions

  • DRUG Hyperpolarized Xe129

Study Locations (1)

Virginia

  • Snyder Building 480 Ray C. Hunt Drive - Charlottesville

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2025-05-01
Est. Completion 2027-12
Phase Early Phase 1
University of Virginia

449 total trials

What NCT06853145 shows while recruiting

NCT06853145 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which Hyperpolarized Xe129 is the first listed.

NCT06853145 reports a single indexed study location in Virginia.

Frequently Asked Questions

What is clinical trial NCT06853145 about?

NCT06853145 is a clinical study titled "Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis". Idiopathic pulmonary fibrosis has a poor prognosis with limited treatment options. The Investigator hypothesize hyperpolarized Xe129-MRI can be performed in patients with IPF and repeated over time which will detect deficiencies related to perfusion in the lung.

What is the current status of trial NCT06853145?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2025-05-01. Estimated completion is 2027-12.

What conditions does trial NCT06853145 study?

This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.

What interventions are being tested in trial NCT06853145?

The interventions under investigation include: Hyperpolarized Xe129 (DRUG).

Who is sponsoring clinical trial NCT06853145?

This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06853145 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Idiopathic Pulmonary Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06853145's enrollment target sits among peer trials

6 52nd of 51 the lowest of 51 other Idiopathic Pulmonary Fibrosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06853145

Source: ClinicalTrials.gov NCT06853145, the US trial registry maintained by the National Library of Medicine. NCT06853145 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.